← All stories
Markets
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
Covered by 1 outlet
All coverage · 1 article